Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target. - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Journal of Medicinal Chemistry Année : 2023

Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target.

Résumé

Receptor interacting serine/threonine protein kinase 2 (RIPK2) is a downstream signaling molecule essential for the activation of several innate immune receptors, including the NOD-like receptors (NOD1 and NOD2). Recognition of pathogen-associated molecular pattern proteins by NOD1/2 leads to their interaction with RIPK2, which induces release of pro-inflammatory cytokines through the activation of NF-κB and MAPK pathways, among others. Thus, RIPK2 has emerged as a key mediator of intracellular signal transduction and represents a new potential therapeutic target for the treatment of various conditions, including inflammatory diseases and cancer. In this Perspective, first, an overview of the mechanisms that underlie RIPK2 function will be presented along with its role in several diseases. Then, the existing inhibitors that target RIPK2 and different therapeutic strategies will be reviewed, followed by a discussion on current challenges and outlook.
Fichier non déposé

Dates et versions

hal-04495289 , version 1 (08-03-2024)

Identifiants

Citer

Morgane Rivoal, Laurent Dubuquoy, Régis Millet, Natascha Chavain. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target.. Journal of Medicinal Chemistry, 2023, Journal of Medicinal Chemistry, ⟨10.1021/acs.jmedchem.3c00593⟩. ⟨hal-04495289⟩

Collections

RIIP UNIV-LILLE
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More